Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10859520 | 0.98 | KDM4E (0.39) | KDM4EGSK3BGABRR1GDASMN1; SMN2 | |
| SCHEMBL22656785 | 0.79 | KDM4E (0.42) | KDM4EGABRR1GDASMN1; SMN2GAA | |
| SCHEMBL12176661 | 0.77 | LMNA (0.45) | KDM4ESMN1; SMN2LMNA | |
| SCHEMBL1667866 | 0.75 | — | — | |
| SCHEMBL5726855 | 0.75 | — | — | |
| SCHEMBL11191356 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL947740 | 0.74 | KDM4E (0.47) | KDM4EGABRR1GDASMN1; SMN2GAA | |
| SCHEMBL11507885 | 0.74 | — | — | |
| SCHEMBL2824171 | 0.73 | GAA (0.53) | KDM4EGDASMN1; SMN2GAATDP1 | |
| Hydrochloric Acid SCHEMBL11084718 | 0.72 | GDA (0.39) | KDM4EGABRR1GDASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| US-4590299-A | 2-guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| US-4510313-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0050458-B1 | 2-GUANIDINO-4-HETEROARYLTHIAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4452987-A | Haloacetyl imidazoles | PFIZER INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4374843-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0050458-A2 | 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them | PFIZER INC. (US) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | KDM4E 458/4885GSK3B 399/4885GABRR1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.